Advances in the diagnosis and treatment of HIV-associated pulmonary arterial hypertension

References

• Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol. 1987 Dec;18(12):1293–1296.
   PubMed Web of Science ®Google Scholar
• Barnett CF, Hsue PY, Machado RF. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA. 2008 Jan 23;299(3):324–331.
   PubMed Web of Science ®Google Scholar
• Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013 Dec;34(46):3538–3546.
   PubMed Web of Science ®Google Scholar
• Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008 Sep;22(Suppl 3):S19–26.
   PubMedGoogle Scholar
• Cannillo M, D’Ascenzo F, Grosso Marra W, et al. Heart failure in patients with human immunodeficiency virus: a review of the literature. J Cardiovasc Med (Hagerstown). 2015 May;16(5):383–389.
   PubMed Web of Science ®Google Scholar
• Cerrato E, D’Ascenzo F, Biondi-Zoccai G, et al. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J. 2013 May;34(19):1432–1436.
   PubMed Web of Science ®Google Scholar
• Staitieh B, Guidot DM. Noninfectious pulmonary complications of human immunodeficiency virus infection. Am J Med Sci. 2014 Dec;348(6):502–511.
   PubMed Web of Science ®Google Scholar
• Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS. 2008 Sep;22(Suppl 3):S35–40.
   PubMedGoogle Scholar
• Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008 Jan 1;177(1):108–113.
   PubMed Web of Science ®Google Scholar
• Farber HW, Miller DP, Poms AD, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015 Oct;148(4):1043–1054.
   PubMed Web of Science ®Google Scholar
• Mehta NJ, Khan IA, Mehta RN, et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest. 2000 Oct;118(4):1133–1141.
   PubMed Web of Science ®Google Scholar
• Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010 Jan 2;24(1):67–75.
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003 May 15;167(10):1433–1439.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016 4;Apr(4):306–322.
   Google Scholar
• Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. Chest. 1991 Nov;100(5):1268–1271.
   PubMed Web of Science ®Google Scholar
• Bigna JJ, Nansseu JR, Noubiap JJ. Pulmonary hypertension in the global population of adolescents and adults living with HIV: a systematic review and meta-analysis. Sci Rep. 2019 May 24;9(1):7837.
   PubMedGoogle Scholar
• de Mendoza C. UNAIDS Update Global HIV Numbers. AIDS Rev. 2019;21(3):170–171.
   PubMed Web of Science ®Google Scholar
• Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses. 2001 Jan 1;17(1):45–53.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS. 2008 Apr 23;22(7):825–833.
   PubMed Web of Science ®Google Scholar
• Mermis J, Gu H, Xue B, et al. Hypoxia-inducible factor-1 alpha/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res. 2011 Aug 5;12:103.
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998 Mar;11(3):554–559.
   PubMed Web of Science ®Google Scholar
• Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun. 2005 Aug 12;333(4):1107–1115.
   PubMed Web of Science ®Google Scholar
• Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis. 1992 May;145(5):1196–1200.
   PubMed Web of Science ®Google Scholar
• Marecki JC, Cool CD, Parr JE, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med. 2006 Aug 15;174(4):437–445.
   PubMed Web of Science ®Google Scholar
• George MP, Champion HC, Simon M, et al. Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013 Mar;48(3):374–381.
   PubMed Web of Science ®Google Scholar
• Almodovar S, Knight R, Allshouse AA, et al. Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses. 2012 Jun;28(6):607–618.
   PubMed Web of Science ®Google Scholar
• Boucherat O, Chabot S, Antigny F, et al. Potassium channels in pulmonary arterial hypertension. Eur Respir J. 2015 Oct;46(4):1167–1177.
   PubMed Web of Science ®Google Scholar
• Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20–31.
   PubMed Web of Science ®Google Scholar
• Mondejar-Parreno G, Morales-Cano D, Barreira B, et al. HIV transgene expression impairs K(+) channel function in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L711–L723.
   PubMed Web of Science ®Google Scholar
• Caldwell RL, Gadipatti R, Lane KB, et al. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol. 2006 Jan;79(1):192–201.
   PubMed Web of Science ®Google Scholar
• Chinnappan M, Mohan A, Agarwal S, et al. Network of MicroRNAs mediate translational repression of bone morphogenetic protein receptor-2: involvement in HIV-associated pulmonary vascular remodeling. J Am Heart Assoc. 2018 Feb 25;7:5.
   Web of Science ®Google Scholar
• Guo ML, Kook YH, Shannon CE, et al. Notch3/VEGF-A axis is involved in TAT-mediated proliferation of pulmonary artery smooth muscle cells: implications for HIV-associated PAH. Cell Death Discov. 2018;4:22.
   PubMed Web of Science ®Google Scholar
• Gérald Simonneau DM, Celermajer DS, Denton CP, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.
   PubMed Web of Science ®Google Scholar
• Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55–66.
   PubMed Web of Science ®Google Scholar
• Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984 Oct;70(4):657–662.
   PubMed Web of Science ®Google Scholar
• Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest. 2011 May;139(5):988–993.
   PubMed Web of Science ®Google Scholar
• Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009 Apr 1;179(7):615–621.
   PubMed Web of Science ®Google Scholar
• Selby VN, Scherzer R, Barnett CF, et al. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. AIDS. 2012 Sep 24;26(15):1967–1969.
   PubMed Web of Science ®Google Scholar
• Yared K, Noseworthy P, Weyman AE, et al. Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. J Am Soc Echocardiogr. 2011 Jun;24(6):687–692.
   PubMed Web of Science ®Google Scholar
• Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary hypertension. Am J Respir Crit Care Med. 2011 Jan 15;183(2):268–276.
   PubMed Web of Science ®Google Scholar
• Takahama H, McCully RB, Frantz RP, et al. Unraveling the RV ejection doppler envelope: insight into pulmonary artery hemodynamics and disease severity. JACC Cardiovasc Imaging. 2017 Oct;10(10Pt B):1268–1277.
   PubMedGoogle Scholar
• Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002 Apr 3;39(7):1214–1219.
   PubMed Web of Science ®Google Scholar
• Bossone E, Bodini BD, Mazza A, et al. Pulmonary arterial hypertension: the key role of echocardiography. Chest. 2005 May;127(5):1836–1843.
   PubMed Web of Science ®Google Scholar
• Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med. 2013 Jun;34(2):283–292.
   PubMed Web of Science ®Google Scholar
• Khunnawat C, Mukerji S, Havlichek D Jr., et al. Cardiovascular manifestations in human immunodeficiency virus-infected patients. Am J Cardiol. 2008 Sep 1;102(5):635–642.
   PubMed Web of Science ®Google Scholar
• Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004 Apr 15;38(8):1178–1185.
   PubMed Web of Science ®Google Scholar
• Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation. 1994 Jun;89(6):2722–2727.
   PubMed Web of Science ®Google Scholar
• Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med. 1997 Mar;155(3):990–995.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA panel. Jama. 2012;308(4):387–402.
   PubMed Web of Science ®Google Scholar
• Health UDo, Services H. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [cited 2020 May 19]. Available from: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
   Google Scholar
• Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect. 2000;40(3):282–284.
   PubMed Web of Science ®Google Scholar
• Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids. 2010;24(1):67–75.
   PubMed Web of Science ®Google Scholar
• Dhillon NK, Li F, Xue B, et al. Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell Mol Biol. 2011 Jul;45(1):40–52.
   PubMed Web of Science ®Google Scholar
• Spikes L, Dalvi P, Tawfik O, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med. 2012 Jun 1;185(11):1235–1243.
   PubMed Web of Science ®Google Scholar
• Akhurst RJ. TGF beta signaling in health and disease. Nat Genet. 2004 Aug;36(8):790–792.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang T, Wang C. Are statins beneficial for the treatment of pulmonary hypertension? Chronic Dis Transl Med. 2017 Dec;3(4):213–220.
   PubMedGoogle Scholar
• Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007 Feb;28(2):88–98.
   PubMed Web of Science ®Google Scholar
• Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005 Dec;4(12):977–987.
   PubMed Web of Science ®Google Scholar
• Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H801–9.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403–1408.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003 Sep 30;108(13):1640–1645.
   PubMed Web of Science ®Google Scholar
• Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H938–45.
   PubMed Web of Science ®Google Scholar
• Tarantelli RA, Schweitzer F, Simon MA, et al. Longitudinal evaluation of pulmonary arterial hypertension in a rhesus macaque (Macaca mulatta) model of HIV Infection. Comp Med. 2018 Dec 1;68(6):461–473.
   PubMed Web of Science ®Google Scholar
• Rabacal W, Schweitzer F, Rayens E, et al. Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH. Sci Rep. 2019 Dec 27;9(1):19832.
   PubMedGoogle Scholar
• Cicalini S, Chinello P, Grilli E, et al. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr HIV Res. 2009 Nov;7(6):589–596.
   PubMed Web of Science ®Google Scholar
• Araujo I, Enjuanes-Grau C, Lopez-Guarch CJ, et al. Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series. World J Cardiol. 2014 Jun 26;6(6):495–501.
   PubMedGoogle Scholar
• Alp S, Schlottmann R, Bauer TT, et al. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS. 2003 Jul 25;17(11):1714–1715.
   PubMed Web of Science ®Google Scholar
• Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS. 2002 Jul 26;16(11):1568–1569.
   PubMed Web of Science ®Google Scholar
• Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIV-related pulmonary hypertension. AIDS. 2001 Sep 7;15(13):1747–1748.
   PubMed Web of Science ®Google Scholar
• Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. Aids. 1999;13(15):101–107.
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000;50(2):99–107.
   PubMed Web of Science ®Google Scholar
• Chinello P, Cicalini S, Pichini S, et al. Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. Infect Dis Rep. 2015 Feb 24;7(1):5822.
   PubMed Web of Science ®Google Scholar
• Chinello P, Cicalini S, Pichini S, et al. Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors. Curr HIV Res. 2012;10(2):162–164.
   PubMed Web of Science ®Google Scholar
• Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011 Jul;51(7):1071–1078.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004 Dec 1;170(11):1212–1217.
   PubMed Web of Science ®Google Scholar
• Barbaro G, Lucchini A, Pellicelli AM, et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart. 2006 Aug;92(8):1164–1166.
   PubMed Web of Science ®Google Scholar
• Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J. 2009 Jan;33(1):92–98.
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008 Jun 10;117(23):3010–3019.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809–818.
   PubMed Web of Science ®Google Scholar
• Venitz J, Zack J, Gillies H, et al. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784–1805.
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2012 Jul 3;60(1):80–81.
   PubMed Web of Science ®Google Scholar
• Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med. 1997 Dec 1;127(11):1043.
   PubMed Web of Science ®Google Scholar
• Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000 Nov;162(5):1846–1850.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 Aug 1;347(5):322–329.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J. 2004 Feb;23(2):321–326.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015 Dec 24;373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Koval CE, Farr M, Krisl J, et al. Heart or lung transplant outcomes in HIV-infected recipients. J Heart Lung Transplant. 2019 Dec;38(12):1296–1305.
   PubMed Web of Science ®Google Scholar
• Arjona Peris M, Revilla López E, Berastegui C, et al. Lung transplant in HIV-infected patients. Single centre experience. J Heart Lung Transplant. 2020;39(4):S81–S82.
   PubMed Web of Science ®Google Scholar